

11. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of:

KGVSPSYRCPCRFFESH	(SEQ ID No. 18)
KGVSLPYRCPCRFFESH	(SEQ ID No. 19)
KGVSLSPRCPCRFFESH	(SEQ ID No. 20)
KGVSLSYPCPCRFFESH	(SEQ ID No. 21)
KGVSP*SYRCPCRFFESH	(SEQ ID No. 22)
KGVSLP*YRCPCRFFESH	(SEQ ID No. 23)
KGVSLSP*RCPCRFFESH	(SEQ ID No. 24)
KGVSLSYP*CPCRFFESH	(SEQ ID No. 25)
KGVSBtdYRCPCRFFESH	(SEQ ID No. 26)
KGVSLBtdRCPCRFFESH	(SEQ ID No. 27)
KGVSLSBtdCPCRFFESH	(SEQ ID No. 28)
KGVSPSYRC	(SEQ ID No. 29)
KGVSLPYRC	(SEQ ID No. 30)
KGVSLSPRC	(SEQ ID No. 31)
KGVSLSYPC	(SEQ ID No. 32)
KGVSP*SYRC	(SEQ ID No. 33)
KGVSLP*YRC	(SEQ ID No. 34)
KGVSLSP*RC	(SEQ ID No. 35)
KGVSLSYP*C	(SEQ ID No. 36)

Q¹²

KGVS**Btd**YRC

(SEQ ID No. 37)


KGVS**L****Btd**RC

(SEQ ID No. 38)

KGVS**L****S****Btd**C

(SEQ ID No. 39)


wherein P* =



with X= Ar, Ar-OH, alkyl and more

Q¹²


and Btd =




X= Alkyl, Ar, Ar-OH and more

Please amend claim 12 as follows:

12. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of (SEQ ID Nos. 40-50):




wherein P* =



with X= Ar, Ar-OH, alkyl and more


and Btd =



X= Alkyl, Ar, Ar-OH and more


Please amend claim 13 as follows:

13. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of (SEQ ID Nos. 51-72):




wherein X is a natural or unnatural amino acid linker between each of the arginines at position 8 in each sequence; and,

wherein P* =



with X = Ar, Ar-OH, alkyl and more

and Btd =



X = Alkyl, Ar, Ar-OH and more

[Please amend claim 14 as follows:]

14. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected

from the group consisting of:

KGVSLSYRCPCRFF-G_n-LKWIQEYLEKALN (SEQ ID No. 74)

KGVSLSYRCPCRFFESH-G_n-LKWIQEYLEKALN (SEQ ID No. 75)

wherein n is an integer from 0 to 10.

Please amend claim 15 as follows:

15. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of:

KGVSLSYRCPCRFF-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No. 76)

KGVSLSYRCPCRFFESH-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No. 77)

where n is an integer from 1 to 20.

Please amend claim 16 as follows:

16. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of:

KGVS~~PS~~YRCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No.78);

KGVS~~L~~PYRCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No.79);

KGVS~~L~~S~~P~~RCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No.80);

KGVSLSY~~P~~CPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No.81);

KGVS~~PS~~YRCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No.82);

KGVS~~L~~PYRCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No.83);

KGVS~~L~~S~~P~~RCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No.84);

KGVSLSY~~P~~CPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No.85);

KGVS~~PS~~YRCPCRFF-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No.86);

KGVS~~L~~PYRCPCRFF-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No.87);

KGVS~~L~~S~~P~~RCPCRFF-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No.88);

KGVSLSY~~P~~CPCRFF-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No.89);

KGVS~~PS~~YRCPCRFFESH-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No.90);

KGVS~~L~~PYRCPCRFFESH-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No.91);

KGVS~~L~~S~~P~~RCPCRFFESH-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No.92);

KGVSLSYPCPCRFFESH- $(CH_2)_n$ -LKWIQEYLEKALN (SEQ ID No.93),

wherein n is an integer from 1 to 20.

Please amend claim 17 as follows:

17. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of:


Q¹²

KGVS**P***SYRCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No. 94);
KGVS**L**P*YRCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No. 95);
KGVS**L**SP*RCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No. 96);
KGVSLS**P***CPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No. 97);
KGVS**P***SYRCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 98);
KGVS**L**P*YRCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 99);
KGVS**L**SP*RCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 100);
KGVSLS**P***CPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 101);
KGVS**P***SYRCPCRFF- $(CH_2)_n$ -LKWIQEYLEKALN (SEQ ID No. 102);
KGVS**L**P*YRCPCRFF- $(CH_2)_n$ -LKWIQEYLEKALN (SEQ ID No. 103);
KGVS**L**SP*RCPCRFF- $(CH_2)_n$ -LKWIQEYLEKALN (SEQ ID No. 104);
KGVSLS**P***CPCRFF- $(CH_2)_n$ -LKWIQEYLEKALN (SEQ ID No. 105);
KGVS**P***SYRCPCRFFESH- $(CH_2)_n$ -LKWIQEYLEKALN (SEQ ID No. 106);
KGVS**L**P*YRCPCRFFESH- $(CH_2)_n$ -LKWIQEYLEKALN (SEQ ID No. 107);
KGVS**L**SP*RCPCRFFESH- $(CH_2)_n$ -LKWIQEYLEKALN (SEQ ID No. 108);
KGVSLS**P***CPCRFFESH- $(CH_2)_n$ -LKWIQEYLEKALN (SEQ ID No. 109);
KGVS**Btd**YRCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No. 110);
KGVS**L****Btd**RCPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No. 111);
KGVSLS**Btd**CPCRFF-GGGG-LKWIQEYLEKALN (SEQ ID No. 112);
KGVS**Btd**YRCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 113);
KGVS**L****Btd**RCPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 114);
KGVSLS**Btd**CPCRFFESH-GGGG-LKWIQEYLEKALN (SEQ ID No. 115);
KGVS**Btd**YRCPCRFF- $(CH_2)_n$ -LKWIQEYLEKALN (SEQ ID No. 116);

KGVSL**Btd**RCPCRFF-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No. 117);
 KGVSL**Btd**CPCRFF-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No. 118);
 KGV**Sbtd**YRCPCRFFESH-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No. 119);
 KGVSL**Btd**RCPCRFFESH-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No. 120);
 KGVSL**Sbtd**CPCRFFESH-(CH₂)_n-LKWIQEYLEKALN (SEQ ID No. 121),


wherein n is an integer from 0 to 20 and

wherein P* =



with X= Ar, Ar-OH, alkyl and more

and Btd =



X= Alkyl, Ar, Ar-OH and more

[Please amend claim 18 as follows:]

18. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of (SEQ ID Nos. 122-125):

KGVSLSYRCPCRFFGGGGGLKWIQEYLEKALN



KGVSLSYRCPCRFFESHGGGGGLKWIQEYLEKALN



KGVSLSYRCPCRFFGGGGGLKWIQEYLEKALN



KGVSLSYRCPCRFFESHGGGGGLKWIQEYLEKALN



Please claim 19 has been amended as follows:

19. (Amended) A CXCR4 antagonist peptide selected from the group consisting of (SEQ ID

Nos. 122-125):

Q¹²
KGVSLSYRCPCRFFGGGGGLKWIQEYLEKALN



KGVSLSYRCPCRFFESHGGGGGLKWIQEYLEKALN



KGVSLSYRCPCRFFGGGGGLKWIQEYLEKALN



KGVSLSYRCPCRFFESHGGGGGLKWIQEYLEKALN



Please amend claim 20 as follows:

20. (Amended) The method of claim 8, wherein the CXCR4 antagonist peptide is selected from the group consisting of:

KGVSLSYRCPCRFFGGGGGSKPGVIFLTKRSRQV (SEQ ID No. 126);

KGVSLSYRCPCRFF(CH₂)_n SKPGVIFLTKRSRQV (SEQ ID No. 127);

KGVSLSYRCPCRFFGGGGGEEWVQKYVDDLELSA (SEQ ID No. 128);